Skip to main content
. Author manuscript; available in PMC: 2007 Aug 21.
Published in final edited form as: Cancer Ther. 2007 May;5(A):151–160.

Table 1. Satraplatin studies in androgen-independent prostate cancer.

Trial Phase Number of patients Regimen Results
CA142-013 (Latif et al, 2005) II 39 S 120 mg/m2/day × 5 d q 4 wks PR:26%; SD:36%; OS:16.7 mos (95% CI, 9.3 – 19.2 mos)
CA142-029 III 14 S 100 mg/m2/day x 5 d q 5 wks + P 10 mg BID (n=7 pts) x 5 d q 5 wks vs P 10 mg BID (n=7) x 5 d q 5 wks No formal analysis; terminated prematurely
EORTC 30972 (Sternberg et al, 2005) III 50 S 100 mg/m2/day x 5 d q 5 wks + P 10 mg BID (n=27 pts) vs. P 10 mg BID (n=23) PSA response: 33.3% (S+P) vs. 8.7% (P); PFS: 5.2 vs. 2.6 mos, p=0.023; OS:, 14.9 versus 11.9 months (NS)
CA142-026 II 10 S 80 - 100 mg/m2/day x 5 d q 3 wks + P 10 mg BID No formal analysis; terminated prematurely
SPARC (Petrylak et al, 2007) III 950 S 80 mg/m2/day × 5 d q 5 wks + P 5 mg BID vs. P 5 mg BID 40% RR; PFS: 11.7 (S+P) vs. 9 wks (P); at 12 mos, 16% (S+P) and 7% (P) had not progressed

Legends: SPARC: SatraPlatin Against Refractory Cancers; PFS: Progression-free survival; OS: overall survival; RR: risk reduction; SD: stable disease; CI: confidence interval; S: Satraplatin; P: Prednisone;mos: months; wks: weeks; d:days; PR: Partial response; NS: Not significant